Opinion|Videos|June 16, 2025

Remaining unmet needs in diverse populations with mHSPC

Enhancing minority enrollment in clinical trials and utilizing real-world data improves drug safety and efficacy for mHSPC treatments.

Future Research Directions

Key Themes:

  • There is a need for continued efforts to improve minority enrollment in clinical trials.
  • The importance of real-world evidence to complement trial data is growing.
  • A combined approach should use trial and real-world data for comprehensive assessment.
  • Future research should prioritize diversity and representation.

Key Points for Physicians:

  • Stay informed about evolving evidence from clinical trials and real-world data.
  • Support efforts to improve diversity in research.
  • Consider contributing to real-world evidence generation.
  • Recognize limitations in current evidence while awaiting more comprehensive data.

Notable Insights: Real-world evidence provides an important complement to clinical trial data, particularly for understanding outcomes in traditionally underrepresented populations.

Clinical Significance: Ongoing commitment to inclusive research and evidence generation will improve the quality and equity of prostate cancer care, particularly for populations historically underrepresented in clinical trials.